Millennium Management’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Millennium Management’s Portfolio IMPL Stock Details IMPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-21,485	Closed	-$9.24K	–	6737
2023 Q3	$9.24K	Buy	+21,485	New	+$20.6K	﹤0.01%	5774
2023 Q2	–	Sell	-29,401	Closed	-$41K	–	6920
2023 Q1	$41K	Buy	+29,401	New	+$70.2K	﹤0.01%	5682
2022 Q4	–	Sell	-31,842	Closed	-$155K	–	7261
2022 Q3	$155K	Sell	31,842 -112,365	-78%	-$860K	﹤0.01%	5792
2022 Q2	$1.34M	Buy	+144,207	New	+$1.05M	﹤0.01%	4097
2022 Q1	–	Sell	-14,827	Closed	-$128K	–	7744
2021 Q4	$128K	Buy	14,827 +4,513	+44%	+$45.1K	﹤0.01%	6154
2021 Q3	$126K	Buy	+10,314	New	+$150K	﹤0.01%	6337

Other funds holding IMPL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Millennium Management's IMPL Position: Q4 2023 in Review

Millennium Management sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 21,485 shares — an estimated $9.24K sold.

Millennium Management first reported a position in IMPL in Q3 2021 and held it in 6 quarters. The position peaked at $1.34M in Q2 2022. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

Millennium Management reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Millennium Management sold 21,485 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $9.24K.
Millennium Management first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Millennium Management's Impel Pharmaceuticals Inc. Common Stock position peaked at $1.34M in Q2 2022.
2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Millennium Management's 13F filing for Q4 2023, filed 14 Feb 2024.